Brief: Summit Therapeutics Q3 Net Income USD -56.3 Million
30/10/2024 11:00
Oct 30 (Reuters) - Summit Therapeutics Q3 EPS USD -0.08. * Q3 operating income USD -58.4 million * Q3 operating expenses USD 58.1 million
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering